JP2014500322A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500322A5
JP2014500322A5 JP2013546262A JP2013546262A JP2014500322A5 JP 2014500322 A5 JP2014500322 A5 JP 2014500322A5 JP 2013546262 A JP2013546262 A JP 2013546262A JP 2013546262 A JP2013546262 A JP 2013546262A JP 2014500322 A5 JP2014500322 A5 JP 2014500322A5
Authority
JP
Japan
Prior art keywords
benzofuran
cyclopropyl
fluorophenyl
methanesulfonamide
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013546262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500322A (ja
JP5918264B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/065558 external-priority patent/WO2012087833A1/en
Publication of JP2014500322A publication Critical patent/JP2014500322A/ja
Publication of JP2014500322A5 publication Critical patent/JP2014500322A5/ja
Application granted granted Critical
Publication of JP5918264B2 publication Critical patent/JP5918264B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013546262A 2010-12-22 2011-12-16 C型肝炎阻害剤およびその使用 Expired - Fee Related JP5918264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426312P 2010-12-22 2010-12-22
US61/426,312 2010-12-22
PCT/US2011/065558 WO2012087833A1 (en) 2010-12-22 2011-12-16 Hepatitis c inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2014500322A JP2014500322A (ja) 2014-01-09
JP2014500322A5 true JP2014500322A5 (enExample) 2015-02-12
JP5918264B2 JP5918264B2 (ja) 2016-05-18

Family

ID=45476645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013546262A Expired - Fee Related JP5918264B2 (ja) 2010-12-22 2011-12-16 C型肝炎阻害剤およびその使用

Country Status (6)

Country Link
US (3) US9173887B2 (enExample)
EP (1) EP2655362A1 (enExample)
JP (1) JP5918264B2 (enExample)
CN (2) CN106986862A (enExample)
CA (1) CA2822357A1 (enExample)
WO (1) WO2012087833A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2016522800A (ja) 2013-04-12 2016-08-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規トリアゾリンチオン誘導体
CN105308032B (zh) 2013-04-12 2017-05-24 拜耳作物科学股份公司 新的三唑衍生物
EA030024B1 (ru) 2013-04-12 2018-06-29 Байер Кропсайенс Акциенгезельшафт Новые производные триазола для борьбы с фитопатогенными вредоносными грибами
DK3043803T3 (da) 2013-09-11 2022-08-01 Univ Emory Nukleotid- og nucleosidsammensætninger og deres anvendelse
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016156294A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Triazol derivatives as fungicides
JP2018516237A (ja) 2015-04-02 2018-06-21 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規な5−置換イミダゾール誘導体
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CR20190128A (es) 2016-09-13 2019-05-15 Bayer Ag Combinaciones de compuesto activo que comprenden un derivado de imidazol sustituido en la posición 5
CN109983010A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 作为用于作物保护的杀真菌剂的1-[2-(1-氯环丙基)-2-羟基-3-(3-苯基-1,2-噁唑-5-基)丙基]-1h-咪唑-5-甲腈衍生物及相关化合物
US20190218188A1 (en) 2016-09-29 2019-07-18 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
EP3519391A1 (en) 2016-09-29 2019-08-07 Bayer CropScience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
SG11202002032SA (en) 2017-09-22 2020-04-29 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CA3076476A1 (en) 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
BR112020009446A2 (pt) 2017-11-13 2020-11-03 Bayer Aktiengesellschaft derivados de tetrazólio propila e seu uso como fungicida
PL3704120T3 (pl) 2017-11-24 2024-09-16 Jubilant Episcribe Llc Związki heterocykliczne jako inhibitory prmt5
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497597A (en) 1967-08-01 1970-02-24 American Cyanamid Co Fungicidal composition and method containing 5-nitro-1,3,4-thiadiazoles
DE3208437A1 (de) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
SE8704248D0 (sv) 1987-10-30 1987-10-30 Haessle Ab Medical use
WO1991000092A1 (en) 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
JP2778009B2 (ja) 1989-09-12 1998-07-23 株式会社リコー 電子写真感光体
US5716964A (en) 1989-12-04 1998-02-10 G.D. Searle & Co. Tetrazolyl substituted imidazo 1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury
KR910011852A (ko) 1989-12-04 1991-08-07 폴 디. 매튜카이티스 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물
AU8205991A (en) 1990-06-12 1992-01-07 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
CA2092305C (en) 1990-09-25 2003-02-11 Alfred P. Spada Compounds having antihypertensive and anti-ischemic properties
GB9026926D0 (en) 1990-12-12 1991-01-30 Smith Kline French Lab Novel process
ZA919797B (en) 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
WO1992010190A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
US5240943A (en) 1991-12-19 1993-08-31 G. D. Searle & Co. Benzopyran class iii antiarrhythmic agents
EP0644762B1 (en) 1992-06-10 1997-12-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds for the treatment of anemia
RU2105005C1 (ru) 1992-07-03 1998-02-20 Кумиай Кемикал Индастри Ко., Лтд. Конденсированное гетероциклическое производное, способ его получения и гербицидное средство
US5317028A (en) 1992-09-08 1994-05-31 Warner-Lambert Co. 7-((substituted)amino)-8((substituted)carbonyl)-methylamino-1-oxaspiro(4,5)decanes useful in Parkinson's disease, dystonia, and other movement disorders
TW253885B (enExample) 1992-12-15 1995-08-11 Ishihara Sangyo Kaisha
JPH08508030A (ja) 1993-03-18 1996-08-27 メルク シヤープ エンド ドーム リミテツド ベンゾイミダゾール誘導体
GB9316890D0 (en) 1993-08-13 1993-09-29 Pilkington Plc Photochromic compounds
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
JPH10513151A (ja) 1994-12-22 1998-12-15 バイオケム ファーマ インコーポレイテッド トロンビン阻害剤としての複素環式ケトアルギニンペプチド
DE69622393T2 (de) 1995-04-27 2002-11-28 Fujisawa Pharmaceutical Co., Ltd. Neue verwendung von pyrazolopyridinverbindungen
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
GB9519077D0 (en) 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19547263C2 (de) 1995-12-07 1999-04-29 Cardiotec Inc Amidinohydrazone vom Benzo[b]furan abgeleiteter Ketone, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2000503984A (ja) 1996-01-22 2000-04-04 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体およびその医薬組成物
WO1997027205A1 (en) 1996-01-23 1997-07-31 The Regents Of The University Of Michigan Imidazo[1,2-a]pyridine c-nucleosides as antiviral agents
US6121309A (en) 1996-03-18 2000-09-19 Eisai Co., Ltd. Fused-ring carboxylic acid derivatives
AU2405697A (en) 1996-04-25 1997-11-12 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
GB9610813D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of benzufuran derivatives
NZ332859A (en) 1996-06-17 2000-06-23 American Home Prod pyridinyl, pyrimidinyl or benzofuranyl methylamino substituted cyclobutene-3,4-dione derivatives
DE19624289A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Pyrrolizin-Verbindungen und deren Verwendung
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
US5990136A (en) 1996-08-21 1999-11-23 Pharmacia & Upjohn Company Isoxazoline derivatives useful as antimicrobials
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998041237A1 (en) 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CN1138765C (zh) 1997-05-30 2004-02-18 法玛西雅厄普约翰美国公司 带有硫代羰基功能基的噁唑烷酮抗菌剂
EP0988289A2 (en) 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
GB9716244D0 (en) 1997-07-31 1997-10-08 Electrophoretics International Pharmaceutical compounds
US6080773A (en) 1997-10-14 2000-06-27 Akzo Nobel, N.V. Benzylamine derivatives which are useful in treating psychiatric disorders
US6630597B1 (en) 1997-12-15 2003-10-07 Transitions Optical, Inc. Photochromic 6-aryl substituted 3H-naphtho(2,1-b)pyrans
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
KR20010034881A (ko) 1998-05-21 2001-04-25 시오노 요시히코 sPLA2 억제 효과를 갖는 피롤로[1,2-b]피리다진 유도체
CA2333947C (en) 1998-06-01 2010-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
US6586638B1 (en) 1999-10-19 2003-07-01 Membrane Extraction Technology Limited Process for removing and recovering of phenolic compounds from aqueous fluids
JP2001139575A (ja) 1999-11-15 2001-05-22 Fujisawa Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
US6461538B2 (en) 1999-12-16 2002-10-08 Fuji Photo Film Co., Ltd. Production process for indolizine compounds and their use in organic light-emitting devices
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
ATE301653T1 (de) 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
CN100540538C (zh) 2001-04-16 2009-09-16 田边三菱制药株式会社 高传导率钙-活化k通道开启剂
WO2003004485A1 (fr) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation
EP1427410A1 (en) 2001-08-30 2004-06-16 Merckle Gmbh Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
EP1447400B1 (en) 2001-10-25 2008-09-17 Asahi Kasei Pharma Corporation Bicyclic compound
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200930291A (en) 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
US6828044B2 (en) 2002-10-25 2004-12-07 Eastman Kodak Company Dopant in an electroluminescent device
UA79834C2 (en) 2002-11-01 2007-07-25 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1599476B1 (en) 2003-02-27 2009-10-14 Neurosearch A/S Novel diazabicyclic aryl derivatives
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
DE602004030017D1 (de) 2003-08-01 2010-12-23 Chugai Pharmaceutical Co Ltd Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
WO2005027901A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20050256150A1 (en) 2004-02-20 2005-11-17 Vladimir Birman Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1746888A2 (en) 2004-05-13 2007-01-31 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TW200612923A (en) 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ES2306275T3 (es) 2004-12-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de cromano y sus usos como ligandos dde receptores 5-ht.
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
DE102005019181A1 (de) 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
EP1945209B1 (en) 2005-08-12 2018-05-30 United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7901793B2 (en) 2005-09-23 2011-03-08 Samsung Mobile Display Co., Ltd. Organic light-emitting compound and organic light-emitting device containing the same
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
JP2009523729A (ja) * 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
WO2007087548A2 (en) 2006-01-25 2007-08-02 Smithkline Beecham Corporation Chemical compounds
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
MX2008012617A (es) 2006-03-31 2008-10-10 Novartis Ag Compuestos organicos.
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7585875B2 (en) 2006-06-06 2009-09-08 Avigen, Inc. Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2044083A1 (en) * 2006-07-14 2009-04-08 Genelabs Technologies, Inc. Antiviral agents
WO2008014219A2 (en) 2006-07-24 2008-01-31 Smithkline Beecham Corporation Thiozolidinedione derivatives as p13 kinase inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
WO2008057855A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101195597A (zh) 2006-12-08 2008-06-11 中国科学院上海药物研究所 1-取代-4,4-二取代氨基硫脲类化合物、其制备方法以及其用途
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2672290A1 (en) 2007-01-15 2008-07-24 The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases Antiviral compounds and methods of using thereof
US7541352B2 (en) 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0811065A2 (pt) 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
WO2008153129A1 (ja) 2007-06-14 2008-12-18 Teijin Pharma Limited 尿酸値低下剤
US8143243B2 (en) 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2193133B1 (en) 2007-09-27 2015-08-19 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazolothiadiazoles for use as protein kinase inhibitors
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
KR20100123717A (ko) 2008-02-12 2010-11-24 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2011512341A (ja) 2008-02-14 2011-04-21 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
KR100929642B1 (ko) 2008-02-20 2009-12-03 주식회사 하이닉스반도체 반도체 소자 및 그의 제조방법
JP2009203203A (ja) 2008-02-29 2009-09-10 Toyo Ink Mfg Co Ltd アントラセン誘導体及びその用途
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
GB0806656D0 (en) 2008-04-11 2008-05-14 Karobio Ab Novel estrogen receptor ligands
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8453322B2 (en) 2008-08-14 2013-06-04 Ddi Global Corp. Manufacturing methods of multilayer printed circuit board having stacked via
US20100056491A1 (en) 2008-08-29 2010-03-04 Memory Pharmaceuticals Corporation 4'-amino cyclic compounds having 5-ht6 receptor affinity
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5416944B2 (ja) 2008-10-23 2014-02-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors

Similar Documents

Publication Publication Date Title
AU2007213451B2 (en) Treatment of Duchenne muscular dystrophy
US12458642B2 (en) Metalloenzyme inhibitor compounds
KR101345473B1 (ko) 헤테로 화합물
JP2013532652A5 (enExample)
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2017505762A5 (enExample)
JP2017523972A5 (enExample)
RU2011116226A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP2014531449A5 (enExample)
JP2007533635A5 (enExample)
JP2013519724A5 (enExample)
RU2012107101A (ru) Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы
US9187437B2 (en) Substituted oxadiazole compounds
JP2021535112A5 (enExample)
JP2024540445A5 (enExample)
ES2533095T3 (es) Agonistas de receptores de esfingosina-1-fosfato
JP2018507234A5 (enExample)
JP2013527847A5 (enExample)
JP2019522628A5 (enExample)
JP2004525183A5 (enExample)
JP2019532052A5 (enExample)
JP2023518474A5 (enExample)
JP2014513122A5 (enExample)
EP2635573A1 (en) Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases